Notifications
Clear all
Nov 19, 2021 1:51 pm
WARNING: THIS POST MAY CONTAIN OPINION.
When AZD7442, the new AstraZeneca’s antibody drug, was given within to patients within three days of developing symptoms their risk of developing severe covid19 was reduced by 88%.
Trials demonstrated at least six months of protection was maintained despite the surge of the delta variant at the time. Hence, once approved this might turn out to be an important option for those where vaccination has not occured or has otherwise not worked for whatever reason.